Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy

BJU InternationalVolume 99, Issue 6 p. 1376-1379 Radiotherapy and androgen deprivation in combination after local surgery (RADICALS): A new Medical Research Council/National Cancer Institute of Canada phase III trial of adjuvant treatment after radical prostatectomy Chris Parker, Chris Parker Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorMatthew R. Sydes, Matthew R. Sydes Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorCharles Catton, Charles Catton Princess Margaret Hospital, Toronto, Ontario, Canada,Search for more papers by this authorHoward Kynaston, Howard Kynaston Department of Urology, University Hospital of Wales, Heath Park, Cardiff,Search for more papers by this authorJohn Logue, John Logue Christie Hospital NHS Trust, Manchester, UK,Search for more papers by this authorClaire Murphy, Claire Murphy Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorRachel C. Morgan, Rachel C. Morgan Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorKilian Mellon, Kilian Mellon Urology Section, University of Leicester, UK,Search for more papers by this authorChris Morash, Chris Morash University of Ottawa, The Ottawa Hospital General Campus, Ottawa,Search for more papers by this authorWendy Parulekar, Wendy Parulekar National Cancer Institute of Canada (NCIC) Clinical Trials Group, Kingston, Ontario, Canada,Search for more papers by this authorMahesh K.B. Parmar, Mahesh K.B. Parmar Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorHeather Payne, Heather Payne Department of Oncology, University College Hospital, London, UK,Search for more papers by this authorColleen Savage, Colleen Savage National Cancer Institute of Canada (NCIC) Clinical Trials Group, Kingston, Ontario, Canada,Search for more papers by this authorJim Stansfeld, Jim Stansfeld Hon. Treasurer, PCaSO Prostate Cancer Network, Emsworth, Hants, UK,Search for more papers by this authorNoel W. Clarke, Noel W. Clarke Salford Royal Hospitals NHS Trust, Salford, UKSearch for more papers by this author(The RADICALS Trial Management Group), (The RADICALS Trial Management Group) Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this author Chris Parker, Chris Parker Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorMatthew R. Sydes, Matthew R. Sydes Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorCharles Catton, Charles Catton Princess Margaret Hospital, Toronto, Ontario, Canada,Search for more papers by this authorHoward Kynaston, Howard Kynaston Department of Urology, University Hospital of Wales, Heath Park, Cardiff,Search for more papers by this authorJohn Logue, John Logue Christie Hospital NHS Trust, Manchester, UK,Search for more papers by this authorClaire Murphy, Claire Murphy Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorRachel C. Morgan, Rachel C. Morgan Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorKilian Mellon, Kilian Mellon Urology Section, University of Leicester, UK,Search for more papers by this authorChris Morash, Chris Morash University of Ottawa, The Ottawa Hospital General Campus, Ottawa,Search for more papers by this authorWendy Parulekar, Wendy Parulekar National Cancer Institute of Canada (NCIC) Clinical Trials Group, Kingston, Ontario, Canada,Search for more papers by this authorMahesh K.B. Parmar, Mahesh K.B. Parmar Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this authorHeather Payne, Heather Payne Department of Oncology, University College Hospital, London, UK,Search for more papers by this authorColleen Savage, Colleen Savage National Cancer Institute of Canada (NCIC) Clinical Trials Group, Kingston, Ontario, Canada,Search for more papers by this authorJim Stansfeld, Jim Stansfeld Hon. Treasurer, PCaSO Prostate Cancer Network, Emsworth, Hants, UK,Search for more papers by this authorNoel W. Clarke, Noel W. Clarke Salford Royal Hospitals NHS Trust, Salford, UKSearch for more papers by this author(The RADICALS Trial Management Group), (The RADICALS Trial Management Group) Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research and the Royal, Marsden NHS Foundation Trust, Sutton, Surrey, Medical Research Council (MRC) Clinical Trials Unit, London, UK,Search for more papers by this author First published: 08 April 2007 https://doi.org/10.1111/j.1464-410X.2007.06844.xCitations: 104 Chris Parker, Academic Unit of Radiotherapy & Oncology, Institute of Cancer Research, Downs Road, Sutton, Surrey SM2 5PT, UK.e-mail: [email protected] Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat REFERENCES 1 Morris SL, Parker C, Huddart R, Horwich A, Dearnaley D. Current opinion on adjuvant and salvage treatment after radical prostatectomy. Clin Oncol (R Coll Radiol) 2004; 16: 277–82 10.1016/j.clon.2004.03.004 CASPubMedWeb of Science®Google Scholar 2 Lee LW, Clarke NW, Ramani VA, Cowan RA, Wylie JP, Logue JP. Adjuvant and salvage treatment after radical prostatectomy: current practice in the UK. Prostate Cancer Prostatic Dis 2005; 8: 229–34 10.1038/sj.pcan.4500816 CASPubMedWeb of Science®Google Scholar 3 Bolla M, Van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572–8 10.1016/S0140-6736(05)67101-2 PubMedWeb of Science®Google Scholar 4 Thompson IM Jr, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329–35 10.1001/jama.296.19.2329 CASPubMedWeb of Science®Google Scholar 5 Wiegel T, Bottke D, Willich N et al. Phase III results of adjuvant radiotherapy (RT) versus ‘wait and see’ (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96–02/AUD AP 09/95). 41st Annual Meeting ASCO, May 13–17, 2005. Orange County Covention Center, Orlando, Florida, 2005 Google Scholar 6 Bolla M, Collette L, Blank L et al. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002; 360: 103–6 10.1016/S0140-6736(02)09408-4 CASPubMedWeb of Science®Google Scholar 7 D’Amico AV, Manola J, Loffredo M, Renshaw AA, DellaCroce A, Kantoff PW. 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial. JAMA 2004; 292: 821–7 10.1001/jama.292.7.821 CASPubMedWeb of Science®Google Scholar 8 Lawton CA, Winter K, Murray K et al. Updated results of the Phase III Radiation Therapy Oncology Group (RTOG) Trial 85–31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 2001; 49: 937–46 10.1016/S0360-3016(00)01516-9 CASPubMedWeb of Science®Google Scholar 9 Eulau SM, Tate DJ, Stamey TA, Bagshaw MA, Hancock SL. Effect of combined transient androgen deprivation and irradiation following radical prostatectomy for prostatic cancer. Int J Radiat Oncol Biol Phys 1998; 41: 735–40 10.1016/S0360-3016(98)00127-8 CASPubMedWeb of Science®Google Scholar 10 King CR, Presti JC Jr, Gill H, Brooks J, Hancock SL. Radiotherapy after radical prostatectomy: does transient androgen suppression improve outcomes? Int J Radiat Oncol Biol Phys 2004; 59: 341–7 10.1016/j.ijrobp.2003.10.015 PubMedWeb of Science®Google Scholar 11 Katz MS, Zelefsky MJ, Venkatraman ES, Fuks Z, Hummer A, Leibel SA. Predictors of biochemical outcome with salvage conformal radiotherapy after radical prostatectomy for prostate cancer. J Clin Oncol 2003; 21: 483–9 10.1200/JCO.2003.12.043 PubMedWeb of Science®Google Scholar 12 Hanks GE, Pajak TF, Porter A et al. Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92–02. J Clin Oncol 2003; 21: 3972–8 10.1200/JCO.2003.11.023 CASPubMedWeb of Science®Google Scholar 13 McLeod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP; Casodex Early Prostate Cancer Trialists’ Group. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. BJU Int 2006; 97: 247–54 10.1111/j.1464-410X.2005.06051.x CASPubMedWeb of Science®Google Scholar Citing Literature Volume99, Issue6June 2007Pages 1376-1379 ReferencesRelatedInformation